Novel and Emerging Targeted Therapies of Colorectal Cancer

被引：4
作者：
Finnberg, Niklas [1 ,2 ]
Gokare, Prashanth
El-Deiry, Wafik S.
机构：
[1] Fox Chase Canc Ctr, Lab Translat Oncol & Expt Canc Therapeut, Dept Med Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[2] Fox Chase Canc Ctr, Mol Therapeut Program, Philadelphia, PA 19111 USA
来源：
CURRENT CLINICAL PHARMACOLOGY | 2015年 / 10卷 / 04期
关键词：
Clinical; colorectal cancer; DPYD; RAS; targeted therapy; TRAIL;
D O I：
10.2174/1574884710666151020095911
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The survival rate of patients with colorectal cancer (CRC) is steadily increasing over the past decade. However, CRC continue to be one of the leading causes of cancer-related fatality in the United States. Current targeted strategies offer limited clinical benefits and the overall survival rate for CRC remains low. Improved understanding of the molecular changes associated with CRC that control growth factor signaling and evasion of cell death allow for the development of improved targeted therapy. This review aims to discuss some of the emerging therapies aimed to target CRC.
引用
收藏
页码：279 / 298
页数：20
相关论文
共 242 条
[91]   TRAIL Signaling and Synergy Mechanisms Used in TRAIL-Based Combination Therapies [J].
Hellwig, Christian T. ;
Rehm, Markus .
MOLECULAR CANCER THERAPEUTICS, 2012, 11 (01) :3-13
[92]   Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer [J].
Herbst, Roy S. ;
Eckhardt, S. Gail ;
Kurzrock, Razelle ;
Ebbinghaus, Scot ;
O'Dwyer, Peter J. ;
Gordon, Michael S. ;
Novotny, William ;
Goldwasser, Meredith A. ;
Tohnya, Tanyifor M. ;
Lum, Bert L. ;
Ashkenazi, Avi ;
Jubb, Adrian M. ;
Mendelson, David S. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (17) :2839-2846
[93]   Mismatch repair deficient colorectal cancer in the era of personalized treatment [J].
Hewish, Madeleine ;
Lord, Christopher J. ;
Martin, Sarah A. ;
Cunningham, David ;
Ashworth, Alan .
NATURE REVIEWS CLINICAL ONCOLOGY, 2010, 7 (04) :197-208
[94]   Is there a role for routine p53 testing in colorectal cancer? [J].
Hoff, PM .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (30) :7395-7396
[95]   VEGF-Trap: A VEGF blocker with potent antitumor effects [J].
Holash, J ;
Davis, S ;
Papadopoulos, N ;
Croll, SD ;
Ho, L ;
Russell, M ;
Boland, P ;
Leidich, R ;
Hylton, D ;
Burova, E ;
Ioffe, E ;
Huang, T ;
Radziejewski, C ;
Bailey, K ;
Fandl, JP ;
Daly, T ;
Wiegand, SJ ;
Yancopoulos, GD ;
Rudge, JS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (17) :11393-11398
[96]   Analysis of Circulating Tumor DNA to Confirm Somatic KRAS Mutations [J].
Holdhoff, Matthias ;
Schmidt, Kerstin ;
Donehower, Ross ;
Diaz, Luis A., Jr. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (18) :1284-1285
[97]  
Holmes J, 1998, TOXICOL SCI, V46, P342, DOI 10.1006/toxs.1998.2558
[98]   Nimotuzumab prolongs survival in patients with malignant gliomas: A phase I/II clinical study of concomitant radiochemotherapy with or without nimotuzumab [J].
Hong, Jidong ;
Peng, Yuping ;
Liao, Yuping ;
Jiang, Wuzhong ;
Wei, Rui ;
Huo, Lei ;
Han, Zaide ;
Duan, Chaojun ;
Zhong, Meizuo .
EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2012, 4 (01) :151-157
[99]   The combination of 5-Fluorouracil plus p53 pathway restoration is associated with depletion of p53-deficient or mutant p53-expressing putative colon cancer stem cells [J].
Huang, Catherine ;
Zhang, Xiang M. ;
Tavaluc, Raluca T. ;
Hart, Lori S. ;
Dicker, David T. ;
Wang, Wenge ;
El-Deiry, Wafik S. .
CANCER BIOLOGY & THERAPY, 2009, 8 (22) :2185-2192
[100]   Sorafenib Inhibits STAT3 Activation to Enhance TRAIL-Mediated Apoptosis in Human Pancreatic Cancer Cells [J].
Huang, Shengbing ;
Sinicrope, Frank A. .
MOLECULAR CANCER THERAPEUTICS, 2010, 9 (03) :742-750
567891011121314